Myogen: Darusentan Enters Phase III

Myogen, Inc. (NASDAQ: MYOG) now has two candidates in Phase III trials, Ambrisentan and now Darusentan. The Darusentan trial will evaluate patients with resistant hypertension (RHTN). RHTN is the "the failure to achieve goal blood pressure in patients who are adhering to full doses of an appropriate three-drug regimen that includes a diuretic."

The primary objective of the trial is to determine if Darusentan is effective in reducing systolic blood pressure in resistant hypertension patients currently treated with full doses of four or more antihypertensive medications, one of which is a diuretic. The primary endpoint of the trial is change from baseline to week 14 in systolic blood pressure as compared to placebo.